Initiation of Various Clinical Trials of PD-1/VEGF Bispecific Antibody (AK112)
2021-05-12
Initiation of Various Clinical Trials of PD-1/VEGF Bispecific Antibody (AK112)
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Approval to Initiate Phase III Clinical Trial for First-Line Treatment of Advanced Cervical Cancer
2021-04-28
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Approval to Initiate Phase III Clinical Trial for First-Line Treatment of Advanced Cervical Cancer
New Level of Production Capacity Expansion Akeso Builds the World’s Largest FlexFactory Platform in Cooperation with Cytiva
2021-04-27
New Level of Production Capacity Expansion Akeso Builds the World’s Largest FlexFactory Platform in Cooperation with Cytiva
Penpulimab (PD-1) Obtained Breakthrough Therapy Designation from FDA for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma
2021-03-30
Penpulimab (PD-1) Obtained Breakthrough Therapy Designation from FDA for Third-Line Treatment of Metastatic Nasopharyngeal Carcinoma
Akeso Guangzhou Manufacturing Base Project Phase I Goes into Operation
2021-03-12
Akeso Guangzhou Manufacturing Base Project Phase I Goes into Operation
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Orphan Drug Designation from FDA of the United States for Treating Cervical Cancer
2021-03-03
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Orphan Drug Designation from FDA of the United States for Treating Cervical Cancer
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
2020-05-25
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
2020-05-11
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer
2020-04-02
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer
开心体育app | 开云新人注册88元 | 竞技宝体育首页 | fb体育官方 | milan米兰官网入口 | mk足球 | 赢博网页 | 澳洲体彩幸运10官网（中国）幸运有限公司 | 悟空官方网站 |